Rice Hall James & Associates LLC Sells 4,632 Shares of Insmed Incorporated (NASDAQ:INSM)

Rice Hall James & Associates LLC lowered its position in shares of Insmed Incorporated (NASDAQ:INSM - Free Report) by 5.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 88,860 shares of the biopharmaceutical company's stock after selling 4,632 shares during the period. Rice Hall James & Associates LLC's holdings in Insmed were worth $6,135,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. V Square Quantitative Management LLC bought a new stake in shares of Insmed during the third quarter valued at approximately $30,000. Spire Wealth Management bought a new stake in shares of Insmed during the fourth quarter valued at approximately $47,000. Exchange Traded Concepts LLC increased its position in shares of Insmed by 522.5% during the third quarter. Exchange Traded Concepts LLC now owns 747 shares of the biopharmaceutical company's stock valued at $55,000 after acquiring an additional 627 shares in the last quarter. Venturi Wealth Management LLC bought a new stake in shares of Insmed during the fourth quarter valued at approximately $86,000. Finally, Blue Trust Inc. increased its position in shares of Insmed by 2,348.8% during the third quarter. Blue Trust Inc. now owns 1,959 shares of the biopharmaceutical company's stock valued at $131,000 after acquiring an additional 1,879 shares in the last quarter.

Analyst Ratings Changes

Several equities research analysts recently weighed in on INSM shares. JPMorgan Chase & Co. raised their price target on shares of Insmed from $83.00 to $92.00 and gave the company an "overweight" rating in a research report on Friday, February 7th. Truist Financial lifted their target price on shares of Insmed from $105.00 to $108.00 and gave the stock a "buy" rating in a research report on Friday. Stifel Nicolaus lowered their target price on shares of Insmed from $97.00 to $96.00 and set a "buy" rating on the stock in a research note on Friday. HC Wainwright restated a "buy" rating and set a $90.00 target price on shares of Insmed in a research note on Friday. Finally, Cantor Fitzgerald restated an "overweight" rating on shares of Insmed in a research note on Wednesday. One investment analyst has rated the stock with a sell rating and fifteen have issued a buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $91.00.

Insider Transactions at Insmed

In other news, insider Orlov S. Nicole Schaeffer sold 91,140 shares of the business's stock in a transaction dated Thursday, January 30th. The shares were sold at an average price of $80.00, for a total value of $7,291,200.00. Following the sale, the insider now directly owns 97,083 shares in the company, valued at $7,766,640. The trade was a 48.42 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Sara Bonstein sold 18,322 shares of the company's stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $80.31, for a total transaction of $1,471,439.82. Following the transaction, the chief financial officer now owns 118,863 shares in the company, valued at $9,545,887.53. The trade was a 13.36 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 532,207 shares of company stock worth $41,400,465 in the last three months. Insiders own 4.60% of the company's stock.

Insmed Price Performance

INSM stock traded down $2.55 during mid-day trading on Friday, hitting $81.06. The company had a trading volume of 2,722,240 shares, compared to its average volume of 1,948,698. The company has a market capitalization of $14.50 billion, a price-to-earnings ratio of -14.61 and a beta of 1.11. Insmed Incorporated has a 12-month low of $21.92 and a 12-month high of $84.91. The company has a quick ratio of 5.99, a current ratio of 6.37 and a debt-to-equity ratio of 2.03. The company has a 50-day moving average price of $74.29 and a 200 day moving average price of $73.59.

Insmed (NASDAQ:INSM - Get Free Report) last posted its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, missing analysts' consensus estimates of ($1.17) by ($0.15). The firm had revenue of $104.44 million for the quarter, compared to analysts' expectations of $102.31 million. On average, research analysts anticipate that Insmed Incorporated will post -5.42 earnings per share for the current year.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.